Mechanism of Action

CAYSTON is the only FDA-approved MONOBACTAM inhaled antibiotic to treat cystic fibrosis (CF) patients with PSEUDOMONAS AERUGINOSA (Pa)

Activity in vitro against Pa, a Gram-negative bacteria

  • The chemical structure confers specificity for aerobic Gram-negative bacteria and enhances beta-lactamase stability
  • Binds to penicillin-binding proteins of susceptible bacteria
  • Leads to inhibition of bacterial cell wall synthesis and death of the cell
  • Activity not decreased in the presence of CF lung secretions
CAYSTON Mechanism of Action graph
Learn About Delivery